Educational only — not medical advice. If you’re in crisis or thinking about suicide: call or text 988 (U.S.) or your local emergency number. Support resources. Under construction and review—see the updates log.

benztropine

Adjunctive therapy

Brand: Cogentin

Published 2025-12-23 · Last reviewed 2025-12-30 · 5 references

Content sourced from FDA labeling (DailyMed) and peer-reviewed literature.

Print sheet Review evidence

At a glance

Class: Adjunctive therapy·Typical dose: Initiate with a low dose and increase gradually in 0.5 mg increments at 5–6 day intervals to the smallest amount necessary for relief; maximum labeled daily dose is 6 mg/day (label).·PK (metabolism / half-life): Contemporary labels for older anticholinergics may not provide detailed pharmacokinetic parameters; practical dosing is guided by clinical response and adverse effects (label/clinical).·LAI available: No

Class: Adjunctive therapy
Typical dose: Initiate with a low dose and increase gradually in 0.5 mg increments at 5–6 day intervals to the smallest amount necessary for relief; maximum labeled daily dose is 6 mg/day (label).
PK (metabolism / half-life): Contemporary labels for older anticholinergics may not provide detailed pharmacokinetic parameters; practical dosing is guided by clinical response and adverse effects (label/clinical).
LAI available: No

Quick answers

What is benztropine?: Benztropine (brand Cogentin; generics) is an anticholinergic antiparkinson agent. In psychiatry it is commonly used to treat antipsychotic-induced Parkinsonism and acute Dystonia, and it is sometimes used for other medication-induced extrapyramidal reactions (label/clinical).
What is Cogentin?: Cogentin is a brand name for benztropine.
What is Cogentin (benztropine) used for?: Label indications include: Parkinsonism; control of extrapyramidal disorders due to neuroleptic drugs (except tardive dyskinesia) (label).
What drug class is Cogentin (benztropine)?: Anticholinergic.
What is the mechanism of action of Cogentin (benztropine)?: Anticholinergic (antimuscarinic) antiparkinson agent used for parkinsonism and to control extrapyramidal reactions caused by neuroleptic drugs (except tardive dyskinesia). In psychiatric practice it is often used short term for drug-induced parkinsonism or acute dystonia, balancing symptomatic benefit against anticholinergic adverse effects (confusion, constipation, urinary retention).
What strengths does Cogentin (benztropine) come in?: Tablets: 0.5 mg, 1 mg, 2 mg (label/manufacturer-dependent).

General information

Benztropine (brand Cogentin; generics) is an anticholinergic antiparkinson agent used for parkinsonism and for extrapyramidal reactions due to neuroleptic drugs, excluding TD (label).

In psychiatric practice it is most often used to treat antipsychotic- induced Parkinsonism and acute Dystonia, balancing symptomatic benefit against anticholinergic adverse effects (label/clinical).

Anticholinergic adverse effects (constipation, urinary retention, blurred vision, confusion) are often the limiting factor, particularly in older adults and in patients with cognitive vulnerability (label/clinical).

Reviews emphasize assessing whether antipsychotic dose reduction or switching is feasible before relying on chronic anticholinergic therapy for drug-induced parkinsonism (Wisidagama 2021/clinical).

The benztropine compare view, evidence feed, and print page support EPS counseling and side-by-side review of common options.

U.S. approvals

Parkinsonism
Control of extrapyramidal disorders due to neuroleptic drugs (except tardive dyskinesia)

Formulations & strengths

Tablets: 0.5 mg, 1 mg, 2 mg (label/manufacturer-dependent).

Generic availability

Available as generic; brand name Cogentin is widely recognized.

Benztropine is often used as a targeted symptomatic agent rather than a chronic default. When possible, minimizing the causative antipsychotic exposure and limiting anticholinergic burden are emphasized, especially in older adults (clinical).

View labelExact

Mechanism of action

Refer to the Glossary entry on Neurotransmitters for background on receptor systems involved in serious mental illness.

Antimuscarinic (anticholinergic) agent that reduces cholinergic tone in basal ganglia and can improve parkinsonism symptoms (mechanism/class).

Benztropine also has antihistaminic properties and has been reported to inhibit dopamine reuptake; clinical effect is largely framed as anticholinergic (mechanism/clinical).

Antimuscarinic (anticholinergic) antiparkinson agent.

Metabolism & pharmacokinetics

Contemporary labels for older anticholinergics may not provide detailed pharmacokinetic parameters; practical dosing is guided by clinical response and adverse effects (label/clinical).

Dosing & administration

Initiate with a low dose and increase gradually in 0.5 mg increments at 5–6 day intervals to the smallest amount necessary for relief; maximum labeled daily dose is 6 mg/day (label).
The usual daily dose is 1–2 mg/day, with a labeled range of 0.5–6 mg/day (label).
For antipsychotic-induced Dystonia, urgent treatment commonly uses parenteral anticholinergics; oral benztropine may be used short term to prevent recurrence once symptoms resolve (clinical).

Monitoring & labs

Anticholinergic adverse-effect monitoring (bowel function, urinary retention, blurry vision, dry mouth, tachycardia) (label/clinical).
Mental status monitoring (confusion/delirium), especially in older adults or when anticholinergic burden is high (clinical).
Screen for glaucoma risk and urinary obstruction symptoms when relevant (label/clinical).
Periodic reassessment for TD symptoms and avoidance of anticholinergic treatment for TD when involuntary movements appear (label/clinical).

If benztropine is continued beyond acute symptom control, periodic reassessment of ongoing need helps avoid long-term anticholinergic burden that can worsen cognition and constipation (clinical).

Adverse effects

FDA boxed warnings

Common side effects (≥10%)

Dry mouth / blurry vision: Common anticholinergic effects; consider dose reduction if function is impaired (label/clinical).
Constipation: Common and potentially serious with high anticholinergic burden; monitor bowel function and avoid unnecessary anticholinergic stacking (label/clinical).
Urinary retention: Risk rises with age and prostate/urinary obstruction; reassess if urinary symptoms occur (label/clinical).
Confusion / delirium: Can occur, especially in older adults or with polypharmacy; reassess anticholinergic burden if cognition worsens (label/clinical).

Other notable effects

Benztropine is not recommended for TD and may worsen TD symptoms (label).
Heat intolerance and reduced sweating can occur; counsel about overheating risk (label).

Interactions

Additive anticholinergic burden occurs with TCAs, first-generation antihistamines, many antipsychotics (notably clozapine), and other anticholinergic agents; regimen review is often higher yield than adding more anticholinergic therapy (clinical).
Alcohol and sedatives can worsen dizziness and falls risk in the setting of anticholinergic load (clinical).
Anticholinergics can counteract cholinesterase inhibitors; co-use is generally avoided when dementia medications are present (clinical).

Other useful information

For antipsychotic-induced parkinsonism, reviews often emphasize first evaluating antipsychotic dose reduction or switching feasibility, then using symptomatic agents when needed (Wisidagama 2021/clinical).
Anticholinergic burden has been associated with worse cognitive performance in schizophrenia-spectrum populations; minimizing unnecessary exposure is a common goal (Georgiou 2021/clinical).
For acute Dystonia management, anticholinergic treatment is a standard approach; follow-up often focuses on preventing recurrence and ensuring the primary antipsychotic regimen is adjusted appropriately (Raja 1998/clinical).

References

Related hubs:SMI toolkit·Support resources